AUTHORS
Andy Kaempf, MS, Alexey V. Danilov, MD, PhD2, Jennifer Effie Amengual, MD3, Sonali Smith, MD, FASCO4, Tanaya Shree, MD,PhD5
AFFILIATIONS
1 Oregon Health & Sciences University, Portland, Oregon, United States
2 City of Hope, Duarte, California, United States
3 Columbia University, New York, New York, United States
4 University of Chicago, Chicago, Illinois, United States
5 Oregon Health & Sciences University, Portland, Oregon, United States
ABSTRACT
Outcomes in Diffuse large B cell lymphoma (DLBCL) decline precipitously with age, with 5-year overall survival of ~45%, 38%, and 22% for those aged 71-75, 76-80, or ≥81, respectively (Shaw J et al, Leuk Lymph, 2019); thus, improved treatments for older DLBCL patients remains a critical unmet need. Recently introduced genomic and microenvironmental classifications of DLBCL raise the promise of personalized medicine, but the degree to which these are distinct in older patients is not well understood. The overall goal of this study was to describe the spectrum of DLBCL genomic and microenvironmental characteristics in older adults, with a future goal of informing precision approaches and identifying potential therapeutic vulnerabilities.
Methods: We extracted and assembled patient-level data from several newly diagnosed DLBCL cohorts: [1] US cohorts represented in Schmitz et al, NEJM, 2018; Wright et al, Cancer Cell, 2020; Chapuy et al, Blood, 2025; and Li et al, Cancer Cell, 2025, that established DLBclass, LymphGen, and LymphoMAP classifications, and [2] a UK cohort represented in Lacy et al, Blood, 2020; and Runge et al, Br J Haematol, 2021, that established Haematological Malignancy Research Network (HMRN) classifications. We excluded plasmablastic lymphoma, primary CNS lymphoma, primary mediastinal B cell lymphoma, and T cell/histiocyte-rich B cell lymphoma. We specifically interrogated the distribution of molecular and microenvironmental classifications in older adults using age cutoffs ranging from 60 to 80 years. We computed purity scores (1 – Gini indices) to understand how varying the age cutoff influenced subclass distribution. χ2 or Fisher’s exact tests compared subclass enrichment and prevalence of specific genetic variants in older versus younger patients.
Results: The aggregate US and UK cohort comprised 1472 patients with newly diagnosed DLBCL, all of whom had genomic classification (DLBclass, LymphGen, and/or HMRN) assigned; 409 of the US cohort had microenvironmental (LymphoMAP) classification available. Among the 633 patients for whom class assignments and specific age (rather than age category) were available, we calculated purity indices for DLBclass assignments at cutoffs of 65, 70, 75, and 80 years: 0.220, 0.230, 0.227, and 0.238, encompassing 51% (n=322), 35% (n=220), 20% (n=125), and 7% (n=42) of patients, respectively, compared to an index of 0.200 for the full cohort. An age cutoff of 70y appeared optimal to balance molecular enrichment and inclusion. At this cutoff, subclass distribution was significantly different between younger and older patients for DLBclass categories (p=0.001), with greatest enrichment for the C5 subclass (35% vs 20%, p<0.001). Overall subclass distribution for LymphGen classification was not significantly different in patients ≥70y (p=0.154) but MCD class frequency was higher (17% vs 11%, p=0.024). Age was only available as dichotomized values cut at 60y for the UK cohort, in which there was a significant difference in HMRN subclass distribution in patients ≥60 (p = 0.003), with significant over-representation of the MYD88 (18% vs 9%, p=0.001) and NOTCH2 (17% vs 11%, p=0.044) classes. PIM1 and MYD88 were more frequently mutated in older patients in both cohorts (US n=633: PIM1 42% vs. 31%, p=0.006; MYD88 28% vs 21%, p=0.048. UK n=839: PIM1 27% vs 19%, p=0.016; MYD88 16% vs 5%, p<0.001). No mutations were significantly less common in older patients. For the 409 patients for whom microenvironmental (LymphoMAP) classifications were available, the exhausted T cell archetype was more prevalent in older patients. Age of 65y appeared to be an optimal cutoff for microenvironmental class enrichment (p=0.014; TEX 30% vs 20%).
Conclusions: Older patients with DLBCL are enriched for specific molecular and microenvironmental subtypes, which may inform the design of novel clinical trials and future individualized approaches. While many trials in older patients use cutoffs of 75y or 80y, younger age cutoffs may be more appropriate when subclass enrichment is desired. As PIM1 mutations can limit the efficacy of BTK inhibitors in DLBCL (Kuo et al, Am J Cancer Res, 2016), their significant enrichment among older patients motivates combination approaches co-targeting BTK and PIM1 in this population. Enrichment of an exhausted T cell-defined microenvironment suggests that front-line therapies targeting T cells may benefit from combination with exhaustion-mitigating strategies.
DISCLOSURES
Tanaya Shree, MD,PhD: Astra Zeneca - Research Funding